Neuraxpharm Buccolam Acquisition Opens Up Opportunities
Strikes Deal With Takeda For The Only Buccal Midazolam Approved Across Europe
Executive Summary
Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.
You may also be interested in...
Neuraxpharm Expands Into The Nordics With New Leader From Viatris
In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam.
Neuraxpharm CEO Confirms Expansion Into New Markets, Including US
In an exclusive interview with Generics Bulletin, Neuraxpharm CEO Jörg-Thomas Dierks reveals that the company plans to expand out of Europe into other markets by acquiring companies in regions such as the US.
Neuraxpharm Enters Japanese Market
Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.